Literature DB >> 33853832

Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer.

Antao Chang1,2, Liang Liu1,3, Justin M Ashby1, Dan Wu1, Yanan Chen2, Stacey S O'Neill4, Shan Huang1,2, Juan Wang1,2, Guanwen Wang1,2, Dongmei Cheng1, Xiaoming Tan1,5, W J Petty6, Boris C Pasche1, Rong Xiang2, Wei Zhang7,3, Peiqing Sun7.   

Abstract

When recruited to promoters, histone 3 lysine 4 (H3K4) methyltransferases KMT2 (KMT2A-D) activate transcription by opening chromatin through H3K4 methylation. Here, we report that KMT2 mutations occur frequently in non-small cell lung cancer (NSCLC) and are associated with high mutation loads and poor survival. KMT2C regulated DNA damage responses (DDR) through direct recruitment to DNA damage sites by Ago2 and small noncoding DNA damage response RNA, where it mediates H3K4 methylation, chromatin relaxation, secondary recruitment of DDR factors, and amplification of DDR signals along chromatin. Furthermore, by disrupting homologous recombination (HR)-mediated DNA repair, KMT2C/D mutations sensitized NSCLC to Poly(ADP-ribose) polymerase inhibitors (PARPi), whose efficacy is unclear in NSCLC due to low BRCA1/2 mutation rates. These results demonstrate a novel, transcription-independent role of KMT2C in DDR and identify high-frequency KMT2C/D mutations as much-needed biomarkers for PARPi therapies in NSCLC and other cancers with infrequent BRCA1/2 mutations. SIGNIFICANCE: This study uncovers a critical role for KMT2C in DDR via direct recruitment to DNA damage sites, identifying high-frequency KMT2C/D mutations as biomarkers for response to PARP inhibition in cancer. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33853832      PMCID: PMC8260460          DOI: 10.1158/0008-5472.CAN-21-0688

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  64 in total

Review 1.  Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark.

Authors:  Alexander J Ruthenburg; C David Allis; Joanna Wysocka
Journal:  Mol Cell       Date:  2007-01-12       Impact factor: 17.970

2.  The miR-17-92 cluster of microRNAs confers tumorigenicity by inhibiting oncogene-induced senescence.

Authors:  Lixin Hong; Maoyi Lai; Michelle Chen; Changchuan Xie; Rong Liao; Young Jun Kang; Changchun Xiao; Wen-Yuan Hu; Jiahuai Han; Peiqing Sun
Journal:  Cancer Res       Date:  2010-09-17       Impact factor: 12.701

3.  CtIP protein dimerization is critical for its recruitment to chromosomal DNA double-stranded breaks.

Authors:  Hailong Wang; Zhengping Shao; Linda Z Shi; Patty Yi-Hwa Hwang; Lan N Truong; Michael W Berns; David J Chen; Xiaohua Wu
Journal:  J Biol Chem       Date:  2012-04-27       Impact factor: 5.157

4.  Histone H2A.Z controls a critical chromatin remodeling step required for DNA double-strand break repair.

Authors:  Ye Xu; Marina K Ayrapetov; Chang Xu; Ozge Gursoy-Yuzugullu; Yiduo Hu; Brendan D Price
Journal:  Mol Cell       Date:  2012-10-30       Impact factor: 17.970

5.  High-resolution profiling of gammaH2AX around DNA double strand breaks in the mammalian genome.

Authors:  Jason S Iacovoni; Pierre Caron; Imen Lassadi; Estelle Nicolas; Laurent Massip; Didier Trouche; Gaëlle Legube
Journal:  EMBO J       Date:  2010-04-01       Impact factor: 14.012

6.  mSignatureDB: a database for deciphering mutational signatures in human cancers.

Authors:  Po-Jung Huang; Ling-Ya Chiu; Chi-Ching Lee; Yuan-Ming Yeh; Kuo-Yang Huang; Cheng-Hsun Chiu; Petrus Tang
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

7.  Comprehensive molecular profiling of lung adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-09       Impact factor: 49.962

8.  DICER, DROSHA and DNA damage response RNAs are necessary for the secondary recruitment of DNA damage response factors.

Authors:  Sofia Francia; Matteo Cabrini; Valentina Matti; Amanda Oldani; Fabrizio d'Adda di Fagagna
Journal:  J Cell Sci       Date:  2016-02-16       Impact factor: 5.285

Review 9.  Therapeutic landscape in mutational triple negative breast cancer.

Authors:  Yaqin Shi; Juan Jin; Wenfei Ji; Xiaoxiang Guan
Journal:  Mol Cancer       Date:  2018-07-14       Impact factor: 27.401

10.  The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer.

Authors:  Theodoros Rampias; Dimitris Karagiannis; Margaritis Avgeris; Alexander Polyzos; Antonis Kokkalis; Zoi Kanaki; Evgenia Kousidou; Maria Tzetis; Emmanouil Kanavakis; Konstantinos Stravodimos; Kalliopi N Manola; Gabriel E Pantelias; Andreas Scorilas; Apostolos Klinakis
Journal:  EMBO Rep       Date:  2019-01-21       Impact factor: 8.807

View more
  5 in total

Review 1.  The role of KMT2 gene in human tumors.

Authors:  Zhi-Long Zhang; Peng-Fei Yu; Zhi-Qiang Ling
Journal:  Histol Histopathol       Date:  2022-03-02       Impact factor: 2.303

Review 2.  Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy.

Authors:  Evelien A J van Genugten; Jetty A M Weijers; Sandra Heskamp; Manfred Kneilling; Michel M van den Heuvel; Berber Piet; Johan Bussink; Lizza E L Hendriks; Erik H J G Aarntzen
Journal:  Front Oncol       Date:  2022-01-07       Impact factor: 6.244

3.  Widespread redundancy in -omics profiles of cancer mutation states.

Authors:  Jake Crawford; Brock C Christensen; Maria Chikina; Casey S Greene
Journal:  Genome Biol       Date:  2022-06-27       Impact factor: 17.906

4.  KMT2C mutation in a Chinese man with primary multidrug-resistant metastatic adenocarcinoma of rete testis: a case report.

Authors:  Yue Zhang; Xiaoyan He; Hui Gao
Journal:  BMC Urol       Date:  2022-08-09       Impact factor: 2.090

5.  A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer.

Authors:  Chenchen Tian; Yufan Wei; Jianjun Li; Zhi Huang; Qiong Wang; Yingxue Lin; Xingping Lv; Yanan Chen; Yan Fan; Peiqing Sun; Rong Xiang; Antao Chang; Shuang Yang
Journal:  Int J Mol Sci       Date:  2022-03-07       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.